ArticleOncotarget2015
Epigenetically downregulated Semaphorin 3E contributes to gastric cancer.
Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 20 citations in OpenAlex.
- Circulating Neurovascular Guidance Molecules and Their Relationship with Peripheral Microvascular Impairment in Systemic Sclerosis.Life (Basel, Switzerland) · 2022Article
- Semaphorin3E/plexinD1 Axis in Asthma: What We Know So Far!Advances in experimental medicine and biology · 2021Article
- KIF23 activated Wnt/β-catenin signaling pathway through direct interaction with Amer1 in gastric cancer.Aging · 2020Article
- New functions of Semaphorin 3E and its receptor PlexinD1 during developing and adult hippocampal formation.Scientific reports · 2018Article
- ICG-001 suppresses growth of gastric cancer cells and reduces chemoresistance of cancer stem cell-like population.Journal of experimental & clinical cancer research : CR · 2017Article
- A unified model of the hierarchical and stochastic theories of gastric cancer.British journal of cancer · 2017Review
- Article
- Overexpression of Semaphorin-3E enhances pancreatic cancer cell growth and associates with poor patient survival.Oncotarget · 2016Article
- Enhanced expression of semaphorin 3E is involved in the gastric cancer development.International journal of oncology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Axon guidance protein Semaphorin 3E (Sema3E) promotes tumor metastasis and suppresses tumor cell death. Here, we demonstrated that Sema3E was decreased in gastric cancer. Its levels were inversely associated with tumor progression. Levels of Sema3E were associated with low p300 and high class I histone deacetylase (class I HDAC). Ectopic expression of Sema3E inhibited proliferation and colony formation of gastric cancer cell lines in vitro and xenografts in vivo. Sema3E overexpression inhibited migration and invasion of gastric cancer cells, which was associated with induction of E-cadherin and reduction of Akt and ERK1/2 phosphorylation. We suggest that silencing of Sema3E contributes to the pathogenesis of gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.